Phase 2b Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Assess the PD Response and Safety of Three Dose Levels of (PB1023) Injection Following 20 Weeks of Weekly SC Dosing in Adults With T2DM

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 593 participants.

Also called NCT01658501

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 593 participants (enrolled count) (from the registry)
Sponsor
PhaseBio Pharmaceuticals Inc. (from the registry)
Registry
  • NCT NCT01658501
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01658501. Randomized; quadruple masking; primary purpose treatment. Start 2012-07 (registry gives no type); primary completion 2013-07 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Phase 2b Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Assess the PD Response and Safety of Three Dose Levels of (PB1023) Injection Following 20 Weeks of Weekly SC Dosing in Adults With T2DM
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
50 mg PB1023
Intervention (Drug)
70 mg PB1023
Intervention (Drug)
100 mg PB1023
Intervention (Drug)
Placebo (0.9% Sodium Chloride)
Intervention (Drug)
Victoza®
Intervention (Other)
Diet and Exercise
Intervention (Drug)
Metformin
Intervention (Drug)
Sulfonylurea
Intervention (Drug)
Metformin and Sulfonylurea
Lead sponsor
PhaseBio Pharmaceuticals Inc. (class: industry)

Record details

Record id
cardio:ct-nct01658501
Content hash
7fb11ce08415198ad81149726cb858c935b22fb3b9baf41a9a78df88487393d9